Future studies should be aimed at determining the specific mechanisms by which VAT regulates CD36 in endothelium and potentially other AT cells as well as how CD36 promotes Kir2.1 impairment in obesity-induced endothelial dysfunction. Here, CD36 is linked to obesity disorder.